Temporal Concept – Page 33

Novartis Advances Remibrutinib for Chronic Spontaneous Urticaria with Promising Long-term Data

1 year ago talkbio0Tagged Agammaglobulinaemia tyrosine kinase, Chronic Spontaneous Urticaria, Inhibitor, Long-term, Novartis, Oral cavity, Phase 3 Clinical Trials, remibrutinib

Novartis, Remibrutinib, Chronic Spontaneous Urticaria, Phase III Trials, Long-term Data, Oral Treatment, Bruton’s Tyrosine Kinase Inhibitor

Early Detection and Personalized Treatment of Colorectal Cancer: The Promise of Whole Genome Sequencing-Based Circulating Tumor DNA Tracking” ###

1 year ago talkbio0Tagged Adjuvant Therapy, Circulating, Circulating Tumor DNA, Colorectal Carcinoma, Detection, Liquid Biopsy, Molecular residual disease, MRD, Personalized Treatment, Whole Genome Sequencing

Circulating tumor DNA (ctDNA), Whole genome sequencing (WGS), Colorectal cancer, Early detection, Personalized treatment, Adjuvant therapy, Molecular residual disease (MRD), Liquid biopsies

The Future of Healthcare: Embracing Omnichannel Care for Seamless Patient Experience

1 year ago talkbio0Tagged digital health, Health care facility, healthcare innovation, Healthcare technology, in-person care, Integrated healthcare delivery, Omnichannel Care, Patient-centric care, Telemedicine, trends qualifier, virtual care

Omnichannel care, Telehealth, Healthcare technology, Patient-centric care, Integrated healthcare delivery, Virtual care, In-person care, Healthcare innovation, Digital health, Healthcare trends

FDA Approves Amgen’s Bkemv, First Interchangeable Biosimilar to Soliris for Rare Blood Disorders ###

1 year ago talkbio0Tagged Alexion, amgen, Approved, AstraZeneca, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hemolytic-Uremic Syndrome, Infrequent, interchangeable, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

Bkemv, Soliris, FDA approval, Interchangeable biosimilar, Rare blood disorders, Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Amgen, AstraZeneca, Alexion Pharmaceuticals

Amgen Secures FDA Approval for Bkemv, the First Interchangeable Biosimilar to Soliris for Rare Blood Disorders

1 year ago talkbio0Tagged amgen, Approved, Atypical, Atypical Hemolytic Uremic Syndrome, Biosimilars, Bkemv, Hematological Disease, Hemolytic-Uremic Syndrome, Infrequent, Paroxysmal, Paroxysmal nocturnal hemoglobinuria, PNH, Soliris, United States Food and Drug Administration

FDA approval, Amgen, Bkemv, Soliris, biosimilar, rare blood disorders, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)